Cipla Ltd. — Regulatory Filings 2018

Oct 29, 2018

29th October 2018

• (1) BSE Ltd Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001
• (2) National Stock Exchange of India Ltd Listing Department Exchange Plaza, 5th floor, Plot no. C/1, G Block, Sandra Kurla Complex, Sandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Dear Sir,

Please find enclosed Press Release dated 29th October, 2018.

Kindly acknowledge the receipt.

Thank you,

Yours faithfully, For Cipla Limited

Ashish Chauhan Senior Manager- Corporate Secretarial

Encl: as above

Press Release

Cipla receives final approval for generic version of Aralez Pharmaceuticals, Inc.'s Toprol XL® (Metoprolol Succinate) ER Tablets 50mg, 100mg, 200mg

Mumbai, India, October 29, 2018: Cipla Limited ("Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Metoprolol ER Tablets 50mg, 100mg, 200mg from the United States Food and Drug Administration (US FDA).

Cipla's Metoprolol ER Tablets 50mg, 100mg, 200mg is AB-rated generic therapeutic equivalent version of Aralez Pharmaceuticals, Inc.'s, Toprol XL®. It is a beta1-selective adrenoceptor blocking agent. Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure, Angina Pectoris, heart failure - for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin. According to IQVIA (IMS Health), Toprol XL® and its generic equivalents had U.S. sales of approximately \$464M for the 12-month period ending Aug 2018.

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology and CNS segments are well-known. Our 44 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Mar'18), 4th largest in the pharma private market in South Africa (IQVIA MAT Jun'18) and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigmchanging offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

For queries, please contact:

Corporate Communications Investor Relations Heena Kanal Naveen Bansal

E-Mail: CorpComm@cipla.com E-Mail: Investor.Relations@cipla.com